Effective treatment of rebamipide on xerostomia in Sjogrens syndrome patients:a pilot study -a double-blind placebo-controlled trial
Phase 2
- Conditions
- Xerostomia in Sjogrens syndrome
- Registration Number
- JPRN-UMIN000010710
- Lead Sponsor
- Tochigi medical center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with a history of treatment or currently on treatment for facial or trigeminal neuropathy. Patients with a history of treatment or currently on treatment salivary gland disorders other than SS within 6 months before start of administration. Patients with diabetes. Patients with hypersensitivity to rebamipide. Patients now taking or who took within one month previously rebamipide. Patients taking other drug for the treatment of gastritis and gastric ulcer. Patients who have or might have upper digestive tract, hepatic or biliary disease. Patients with severe hepatic dysfunction or renal dysfunction. Women who are pregnant or who might be pregnant or lactating mothers.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Amount of increase in the unstimulated whole saliva secretion after administration 8W
- Secondary Outcome Measures
Name Time Method